CoChat

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments

Open access

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: It has been suggested that circulating fibrocytes and endothelial cells actively participate in the intense remodelling of the pulmonary vasculature in patients with idiopathic pulmonary fibrosis (IPF). Indeed, fibrotic areas exist that have fewer blood vessels, whereas adjacent non-fibrotic tissue is highly vascularized. The number of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) might reflect the balance between vascular injury and repair. Thus, fibrocytes as well as endothelial cells could potentially be used as biomarkers of disease progression and treatment outcome. METHODS: Peripheral blood samples were collected from 67 patients with a multidisciplinary diagnosis of IPF and from 45 age-matched and sex-matched healthy volunteers. Buffy coat was isolated according to standard procedures and at least 20 million cells were stained with different monoclonal antibodies for the detection of CEC, EPC and circulating fibrocytes. For the detection of CEC and EPC, cells were stained with anti-CD45, anti-CD34, anti-CD133, anti-CD14, anti-CD309 and with the viability probe Far-Red LIVE/DEAD. For the detection of circulating fibrocytes, cells were first stained with LIVE/DEAD and the following monoclonal antibodies: anti-CD3, anti-CD19, anti-CD45, anti-CD34 and anti-CD14, then cells were fixed, permeabilized and stained with fluorochrome-conjugated anti-collagen I monoclonal antibodies. RESULTS: Patients with IPF displayed almost undetectable levels of circulating fibrocytes, low levels of CEC, and normal levels of EPC. Patients treated with nintedanib displayed higher levels of CEC, but lower levels of endothelial cells expressing CD309 (the type II receptor for vascular endothelial growth factor). Treatment with both nintedanib and pirfenidone reduced the percentage of CEC and circulating fibrocytes. CONCLUSIONS: Levels of CEC were reduced in patients with IPF as compared to healthy individuals. The anti-fibrotic treatments nintedanib and pirfenidone further reduced CEC levels. These findings might help explain the mechanism of action of these drugs and should be explored as predictive biomarkers in IPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-015-0515-0

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Gating strategy for the identification of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC). Debris, monocytes and dead cells were excluded by the use of an electronic gate and the dump channel, containing cells identified by mAbs against CD14 and a viability marker, i.e. LIVE/DEAD. CEC and EPC were identified on the basis of the expression of CD34, CD45 and CD133: CEC were defined as CD45dim, CD34+ and CD133− while EPC were defined as CD45−, CD34+ and CD133+. The expression of CD309 (VEGFR-2, KDR) was detected among EPC and CEC. FSC forward scatter, SSC side scatter
Fig. 1 Gating strategy for the identification of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC). Debris, monocytes and dead cells were excluded by the use of an electronic gate and the dump channel, containing cells identified by mAbs against CD14 and a viability marker, i.e. LIVE/DEAD. CEC and EPC were identified on the basis of the expression of CD34, CD45 and CD133: CEC were defined as CD45dim, CD34+ and CD133− while EPC were defined as CD45−, CD34+ and CD133+. The expression of CD309 (VEGFR-2, KDR) was detected among EPC and CEC. FSC forward scatter, SSC side scatterCC BY · PubMed Central
Fig. 2 Gating strategy for the identification of circulating collagen I+ cells, i.e. fibrocytes. Debris, B cells, monocytes and dead cells were removed by an electronic gate as described in the legend to Fig. 1. Circulating fibrocytes were identified as CD34+, CD45+ and collagen I+. The expression of CXCR4 was then evaluated among circulating fibrocytes. Lower panels, referred to cultured human fibroblasts, represents a positive control of collagen I staining (>95 % cells were positive). FSC forward scatter, SSC side scatter
Fig. 2 Gating strategy for the identification of circulating collagen I+ cells, i.e. fibrocytes. Debris, B cells, monocytes and dead cells were removed by an electronic gate as described in the legend to Fig. 1. Circulating fibrocytes were identified as CD34+, CD45+ and collagen I+. The expression of CXCR4 was then evaluated among circulating fibrocytes. Lower panels, referred to cultured human fibroblasts, represents a positive control of collagen I staining (>95 % cells were positive). FSC forward scatter, SSC side scatterCC BY · PubMed Central
Fig. 3 Percentages of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) in patients with idiopathic pulmonary fibrosis (IPF) and healthy participants. Scatter plots and median (line) indicating (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC in healthy donors (CTR) and patients (IPF). P-values, calculated using a Mann–Whitney test, are indicated in the figure
Fig. 3 Percentages of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) in patients with idiopathic pulmonary fibrosis (IPF) and healthy participants. Scatter plots and median (line) indicating (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC in healthy donors (CTR) and patients (IPF). P-values, calculated using a Mann–Whitney test, are indicated in the figureCC BY · PubMed Central
Fig. 4 Percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with idiopathic pulmonary fibrosis treated with different therapies. Bar plots with error bars (mean + standard error of the mean) indicating (a) the percentage of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the percentage of EPC expressing CD309; (e) circulating collagen I+ cells; (f) the amount of CXCR4 among fibrocytes in untreated patients (UNTR) and in patients treated with pirfenidone (PIR) or nintedanib (NIN). P-values, calculated using a Kruskal–Wallis test, only significant values are displayed
Fig. 4 Percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with idiopathic pulmonary fibrosis treated with different therapies. Bar plots with error bars (mean + standard error of the mean) indicating (a) the percentage of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the percentage of EPC expressing CD309; (e) circulating collagen I+ cells; (f) the amount of CXCR4 among fibrocytes in untreated patients (UNTR) and in patients treated with pirfenidone (PIR) or nintedanib (NIN). P-values, calculated using a Kruskal–Wallis test, only significant values are displayedCC BY · PubMed Central
Fig. 5 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in all treated patients with idiopathic pulmonary fibrosis after 6 months of treatment. Before-and-after graphs indicate the trends of different cell populations: (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating collagen I+ cells; and (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values are displayed
Fig. 5 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in all treated patients with idiopathic pulmonary fibrosis after 6 months of treatment. Before-and-after graphs indicate the trends of different cell populations: (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating collagen I+ cells; and (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values are displayedCC BY · PubMed Central
Fig. 6 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with idiopathic pulmonary fibrosis treated with nintedanib after 6 months of treatment. Before-and-after graphs indicate the trend of different cell populations: (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating collagen I+ cells; (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values are displayed
Fig. 6 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with idiopathic pulmonary fibrosis treated with nintedanib after 6 months of treatment. Before-and-after graphs indicate the trend of different cell populations: (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating collagen I+ cells; (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values are displayedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 30

Metadata

Authors
De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Montanari, G., Luppi, F., Carbonelli, C. M., Zucchi, L., Bocchino, M., Zamparelli, A. S., Vancheri, C., Sgalla, G., Richeldi, L., & Cossarizza, A.
Affiliations
  • University of Modena and Reggio Emilia (IT)
  • Santa Maria Nuova Hospital (IT)
  • Federico II University Hospital (IT)
  • University of Catania (IT)
  • University of Southampton (GB)
Corresponding author
Cossarizza, Andrea
Venue
BMC Medicine
Published
2015-11-09
Volume
13
Issue
1
Pages
277-277
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2167302483
Cited by
28
References
43
Citations by year
2025: 3 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 4
FWCI
2.90
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, other-oa)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Funders
AIFA (MRAR08C010)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
idiopathic pulmonary fibrosis, circulating endothelial cells, endothelial progenitor cells, circulating fibrocytes, nintedanib, pirfenidone, antifibrotic therapy, vascular endothelial growth factor receptor, pulmonary vascular remodeling, biomarkers, disease progression
MeSH terms
Aged, Aged, 80 and over, Female, Humans, Male, Pyridones, Biomarkers, Disease Progression, Vascular Endothelial Growth Factor A, Endothelial Cells, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. https://app.cochat.ai/papers/10.1186/s12916-015-0515-0
The paper
De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Montanari, G., Luppi, F., Carbonelli, C. M., Zucchi, L., Bocchino, M., Zamparelli, A. S., Vancheri, C., Sgalla, G., Richeldi, L., & Cossarizza, A. (2015). Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine. https://doi.org/10.1186/s12916-015-0515-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.